Europa · Agencias y tiempo real · ANP

Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa

Publicado por ANP · Países Bajos hace 9 h

SD-101 (Zorblesia™) is the First Topical Therapy Being Developed to Treat Wounds and Lesions Across the Entire Skin Surface in Patients with Three Major Subtype ...

Leer el artículo completo en ANP Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (persportaal.anp.nl)

Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa

También te puede interesar

European gas futures top $1,050, first time since December 2022

QatarEnergy signs deal to buy 4 million tons of US LNG annually through 2054

Hermes revenue growth slows as Chinese consumers cut spending on accessories

Millions of hacking attempts as companies, governments rush to patch PHP flaws

France's 24-year high borrowing costs could be 'warm up for Germany'

LSEG to buy Octus in $3.5 billion deal to shield from AI disruption

Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa

Compartir

También te puede interesar

European gas futures top $1,050, first time since December 2022

QatarEnergy signs deal to buy 4 million tons of US LNG annually through 2054

Hermes revenue growth slows as Chinese consumers cut spending on accessories

Millions of hacking attempts as companies, governments rush to patch PHP flaws

France's 24-year high borrowing costs could be 'warm up for Germany'

LSEG to buy Octus in $3.5 billion deal to shield from AI disruption